{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:21:03Z","timestamp":1764937263468,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Modra Pharmaceuticals BV"},{"name":"Netherlands Cancer Institute"},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["40-41200-98-004"],"award-info":[{"award-number":["40-41200-98-004"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00280-021-04259-5","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T14:02:41Z","timestamp":1616248961000},"page":"855-869","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006\/r in patients with prostate cancer versus patients with other advanced solid tumours"],"prefix":"10.1007","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2674-1291","authenticated-orcid":false,"given":"Marit A. C.","family":"Vermunt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa T.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J. M. A.","family":"Hendrikx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred H.","family":"Schinkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent A.","family":"de Weger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"van der Putten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baukelien","family":"van Triest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andries M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"key":"4259_CR1","unstructured":"Sanofi-Aventis (2005) Taxotere, INN-docetaxel\u2014European Medicines Agency. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/taxotere. Accessed 01 Dec 2020"},{"key":"4259_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512","journal-title":"N Engl J Med"},{"key":"4259_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale CL, Burdett S, Rydzewska LHM et al (2016) Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 17:243\u2013256","journal-title":"Lancet Oncol"},{"key":"4259_CR4","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","volume":"35","author":"L Horn","year":"2017","unstructured":"Horn L, Spigel DR, Vokes EE et al (2017) Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35:3924\u20133933","journal-title":"J Clin Oncol"},{"key":"4259_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3816\/CBC.2000.n.002","volume":"1","author":"JA Sparano","year":"2000","unstructured":"Sparano JA (2000) Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 1:32\u201340","journal-title":"Clin Breast Cancer"},{"key":"4259_CR6","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/cam4.2003","volume":"8","author":"AHM De Vries Schultink","year":"2019","unstructured":"De Vries Schultink AHM, Crombag MBS, van Werkhoven E et al (2019) Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: a meta-analysis and evaluation of a clinical cohort. Cancer Med 8:1406\u20131415","journal-title":"Cancer Med"},{"key":"4259_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4155\/cli.13.18","volume":"3","author":"JP Flores","year":"2013","unstructured":"Flores JP, Saif MW (2013) Novel oral taxane therapies: recent phase I results. Clin Investig (Lond) 3:333\u2013341","journal-title":"Clin Investig (Lond)"},{"key":"4259_CR8","doi-asserted-by":"publisher","first-page":"8996","DOI":"10.1158\/0008-5472.CAN-09-2915","volume":"69","author":"RA Van Waterschoot","year":"2009","unstructured":"Van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY et al (2009) Abscence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 69:8996\u20139002","journal-title":"Cancer Res"},{"key":"4259_CR9","first-page":"6158","volume":"62","author":"HA Bardelmeijer","year":"2002","unstructured":"Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JHM, Beijnen JH et al (2002) Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 62:6158\u20136164","journal-title":"Cancer Res"},{"key":"4259_CR10","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-08-2944","volume":"15","author":"RL Oostendorp","year":"2009","unstructured":"Oostendorp RL, Huitema A, Rosing H, Jansen RS, Ter Heine R, Keessen M et al (2009) Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin Cancer Res 15:4228\u20134233","journal-title":"Clin Cancer Res"},{"key":"4259_CR11","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1158\/1078-0432.CCR-17-2299","volume":"25","author":"VA De Weger","year":"2019","unstructured":"De Weger VA, Stuurman FE, Koolen SLW, Moes JJ, Hendrikx JJMA, Sawicki E et al (2019) A phase I dose escalation study of once-weekly oral administration of docetaxel as ModraDoc001 capsule or ModraDoc006 tablet in combination with ritonavir. Clin Cancer Res 25:5466\u20135474","journal-title":"Clin Cancer Res"},{"key":"4259_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ejca.2017.09.010","volume":"86","author":"VA De Weger","year":"2017","unstructured":"De Weger VA, Stuurman FE, Hendrikx J et al (2017) A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. Eur J Cancer 86:217\u2013225","journal-title":"Eur J Cancer"},{"key":"4259_CR13","doi-asserted-by":"publisher","first-page":"v325","DOI":"10.1093\/annonc\/mdz248.056","volume":"30","author":"MAC Vermunt","year":"2019","unstructured":"Vermunt MAC, Janssen JM, Vrijenhoek GL, Van der Poel HG, Thijssen B, Beijnen JH et al (2019) Addition of an oral docetaxel treatment (ModraDoc006\/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer. Ann Oncol 30:v325\u2013v355","journal-title":"Ann Oncol"},{"key":"4259_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1367","author":"M Vermunt","year":"2020","unstructured":"Vermunt M, Robbrecht D, Devriese L, Janssen J, Keessen M, Eskens F et al (2021) ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006\/r), in metastatic castration-resistant prostate cancer patients: a phase Ib study. Cancer Rep (Hoboken). https:\/\/doi.org\/10.1002\/cnr2.1367","journal-title":"Cancer Rep (Hoboken)"},{"key":"4259_CR15","unstructured":"ModraDoc006\/r in patients with breast cancer. Identifier NCT03890744.\u00a0https:\/\/www.clinicaltrials.gov. Accessed 01 Dec 2020"},{"key":"4259_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS268","volume":"38","author":"UN Vaishampayan","year":"2020","unstructured":"Vaishampayan UN, De Wit EJ, Shore ND, Dreicer R, George DJ, Boccia RV et al (2020) A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006\/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388). J Clin Oncol 38:268\u2013268","journal-title":"J Clin Oncol"},{"key":"4259_CR17","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ijpharm.2016.07.068","volume":"511","author":"E Sawicki","year":"2016","unstructured":"Sawicki E, Beijnen JH, Schellens JHM, Nuijen B (2016) Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel. Int J Pharm 511:765\u2013773","journal-title":"Int J Pharm"},{"key":"4259_CR18","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1016\/j.jchromb.2011.08.034","volume":"879","author":"JJ Hendrikx","year":"2011","unstructured":"Hendrikx JJ, Hillebrand MJ, Thijssen B, Rosing H, Schinkel AH, Schellens JHM, Beijnen JH (2011) A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 879:2984\u20132990","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"4259_CR19","unstructured":"RC Team (2009) R: a language and environment for statistical computing. R foundation for statistical computing, Vienna. https:\/\/www.r-project.org. Accessed 01 Dec 2020"},{"key":"4259_CR20","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1002\/ijc.25279","volume":"127","author":"RA Van Waterschoot","year":"2010","unstructured":"Van Waterschoot RA, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH (2010) Individual and combined roles of CYP3A, P-glycoprotein (MDR1\/ABCB1) and MRP2 (ABBC2) in the pharmacokinetics of docetaxel. Int J Cancer 127:2959\u20132964","journal-title":"Int J Cancer"},{"key":"4259_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/ijc.28970","volume":"136","author":"D Iusuf","year":"2015","unstructured":"Iusuf D, Hendrikx JJ, van Esch A, van de Steeg E, Wagenaar E, Rosing H et al (2015) Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel. Int J Cancer 136:225\u2013233","journal-title":"Int J Cancer"},{"key":"4259_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","volume":"35","author":"A Hsu","year":"1998","unstructured":"Hsu A, Granneman GR, Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275\u2013291","journal-title":"Clin Pharmacokinet"},{"key":"4259_CR23","doi-asserted-by":"publisher","first-page":"18422","DOI":"10.1073\/pnas.1010693107","volume":"107","author":"IF Sevrioukova","year":"2010","unstructured":"Sevrioukova IF, Poulos TL (2010) Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci USA 107:18422\u201318427","journal-title":"Proc Natl Acad Sci USA"},{"key":"4259_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/138920008784220664","volume":"9","author":"SF Zhou","year":"2008","unstructured":"Zhou SF (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310\u2013322","journal-title":"Curr Drug Metab"},{"key":"4259_CR25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ctrv.2015.04.012","volume":"41","author":"AJM Nieuweboer","year":"2015","unstructured":"Nieuweboer AJM, de Morr\u00e9e ES, de Graan AJM, Sparreboom A, de Wit R, Mathijssen RHJ (2015) Inter-patient variability in docetaxel pharmacokinetics: a review. Cancer Treat Rev 41:605\u2013613","journal-title":"Cancer Treat Rev"},{"key":"4259_CR26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1067\/mcp.2002.128388","volume":"72","author":"CL Cummins","year":"2002","unstructured":"Cummins CL, Chi-Yuan Wu, Benet LZ (2002) Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 72:474\u2013489","journal-title":"Clin Pharmacol Ther"},{"key":"4259_CR27","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2010.30.7025","volume":"28","author":"RM Franke","year":"2010","unstructured":"Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A (2010) Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562\u20134567","journal-title":"J Clin Oncol"},{"key":"4259_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00280-007-0613-6","volume":"62","author":"PR Hutson","year":"2008","unstructured":"Hutson PR, Oettel K, Douglas J, Ritter M, Messing E et al (2008) Effect of medical castration on CYP3A4 activity using the erythromycin breath test. Cancer Chemother Pharmacol 62:373\u2013377","journal-title":"Cancer Chemother Pharmacol"},{"key":"4259_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejca.2005.08.035","volume":"42","author":"RHJ Mathijssen","year":"2006","unstructured":"Mathijssen RHJ, van Schaik RHN (2006) Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment. Eur J Cancer 42:141\u2013148","journal-title":"Eur J Cancer"},{"key":"4259_CR30","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40265-013-0036-0","volume":"73","author":"KC S\u00f6derberg L\u00f6fdal","year":"2013","unstructured":"S\u00f6derberg L\u00f6fdal KC, Andersson ML, Gustafsson LL (2013) Cytochrome P450-mediated changes in oxycodone pharmacokinetics\/pharmacodynamics and their clinical implications. Drugs 73:533\u2013543","journal-title":"Drugs"},{"key":"4259_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/bcp.13129","volume":"83","author":"EJM Kuip","year":"2017","unstructured":"Kuip EJM, Zandvliet ML, Koolen SLW, Mathijssen RHJ, van der Rijt CCD (2017) A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. Br J Clin Pharmacol 83:294\u2013313","journal-title":"Br J Clin Pharmacol"},{"key":"4259_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/11317580-000000000-00000","volume":"49","author":"G Franco-Salinas","year":"2010","unstructured":"Franco-Salinas G, de la Rosette JJMCH, Michel MC (2010) Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet 49:177\u2013188","journal-title":"Clin Pharmacokinet"},{"key":"4259_CR33","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.jpainsymman.2017.11.016","volume":"55","author":"H Westdorp","year":"2018","unstructured":"Westdorp H, Kuip EJM, van Oort IM, Kramers C, Gerritsen WR, Vissers KCP (2018) Difficulties in pain management using oxycodone and fentanyl in enzalutamide-treated patients with advanced prostate cancer. J Pain Symptom Manag 55:e6-8","journal-title":"J Pain Symptom Manag"},{"key":"4259_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00008571-200004000-00001","volume":"10","author":"DS Streetman","year":"2000","unstructured":"Streetman DS, Bertino JS, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187\u2013216","journal-title":"Pharmacogenetics"},{"key":"4259_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1517\/17425255.2016.1163337","volume":"12","author":"N Hohmann","year":"2016","unstructured":"Hohmann N, Haefeli WE, Mikus G (2016) CYP3A activity: towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol 12:479\u2013497","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4259_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/sj.clpt.6100050","volume":"81","author":"U Fuhr","year":"2007","unstructured":"Fuhr U, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the \u201ccocktail\u201d approach. Clin Pharmacol Ther 81:270\u2013283","journal-title":"Clin Pharmacol Ther"},{"key":"4259_CR37","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1158\/1541-7786.MCR-16-0477","volume":"15","author":"TM Sissung","year":"2017","unstructured":"Sissung TM, Ley AM, Strope JD, McCrea EM, Beedie S, Peer CJ et al (2017) Differential expression of OATP1B3 mediates unconjugated testosterone influx. Mol Cancer Res 15:1096\u20131105","journal-title":"Mol Cancer Res"},{"key":"4259_CR38","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/bjc.2016.251","volume":"115","author":"ES De Morr\u00e9e","year":"2016","unstructured":"De Morr\u00e9e ES, B\u00f6ttcher R, van Soest RJ, Aghai A, de Ridder CM, Gibson AA et al (2016) Loss of SLCO1B3 drives taxane resistance in prostate cancer. Br J Cancer 115:674\u2013681","journal-title":"Br J Cancer"},{"key":"4259_CR39","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41416-020-01105-y","volume":"123","author":"L Mout","year":"2020","unstructured":"Mout L, Moll JM, Chen M, de Morr\u00e9e ES, de Ridder CMA, Gibson A et al (2020) Androgen receptor signaling impairs docetaxel efficacy in castration-resistant prostate cancer. Br J Cancer 123:1715\u20131719","journal-title":"Br J Cancer"},{"key":"4259_CR40","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/jps.24564","volume":"105","author":"T De Bruyn","year":"2016","unstructured":"De Bruyn T, Stieger B, Augustijns PF, Annaert PP (2016) Clearance prediction of HIV protease inhibitors in man: role of hepatic uptake. J Pharm Sci 105:854\u2013863","journal-title":"J Pharm Sci"},{"key":"4259_CR41","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/00008571-199810000-00004","volume":"8","author":"M Shou","year":"1998","unstructured":"Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV (1998) Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:394\u2013401","journal-title":"Pharmacogenetics"},{"key":"4259_CR42","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/carcin\/bgl222","volume":"28","author":"AM Moilanen","year":"2007","unstructured":"Moilanen AM, Hakkola J, Vaarala MH, Kauppila S, Hirvikoski P, Vuoristo J et al (2007) Characterization of androgen-regulated expression of CYP3A5 in human prostate. Carcinogenesis 28:916\u2013921","journal-title":"Carcinogenesis"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04259-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04259-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04259-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:11:09Z","timestamp":1628590269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04259-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["4259"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04259-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2021,3,20]]},"assertion":[{"value":"31 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jos H Beijnen is a part time employee and shareholder of Modra Pharmaceuticals BV and is a patent holder on oral taxane formulations. Eric van der Putten is a part-time employee and director of Modra Pharmaceuticals BV and is a partner at Aglaia Oncology Funds, which has investments in Modra Pharmaceuticals BV. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The three studies were approved by the Medical Ethical Committee of the Netherlands Cancer Institute. The studies were performed in line with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before start of any study procedures according to Good Clinical Practice.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Since all data are anonymized before publication, no additional consents are needed for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}